These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 38421436)

  • 21. Evaluation of the impact of rifampicin on the plasma concentration of linezolid in tuberculosis co-infected patients.
    Yan P; Shi QZ; Hu YX; Zeng Y; Lu H
    Front Pharmacol; 2023; 14():1260535. PubMed ID: 38026932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic drug management of linezolid: a missed opportunity for clinicians?
    Cattaneo D; Gervasoni C; Cozzi V; Castoldi S; Baldelli S; Clementi E
    Int J Antimicrob Agents; 2016 Dec; 48(6):728-731. PubMed ID: 27769709
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and preliminary safety of high dose linezolid for the treatment of Gram-positive bacterial infections.
    Lopez-Garcia B; Luque S; Roberts JA; Grau S
    J Infect; 2015 Nov; 71(5):604-7. PubMed ID: 26099449
    [No Abstract]   [Full Text] [Related]  

  • 24. Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic/pharmacodynamic analysis.
    Gatti M; Raschi E; De Ponti F
    Eur J Clin Pharmacol; 2021 Feb; 77(2):233-239. PubMed ID: 32901348
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review.
    Chiappini E; Conti C; Galli L; de Martino M
    Clin Ther; 2010 Jan; 32(1):66-88. PubMed ID: 20171414
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessing potential drug-drug interactions between clofazimine and other frequently used agents to treat drug-resistant tuberculosis.
    Kengo A; Nabeemeeah F; Denti P; Sabet R; Okyere-Manu G; Abraham P; Weisner L; Mosala MH; Tshabalala S; Scholefield J; Resendiz-Galvan JE; Martinson NA; Variava E
    Antimicrob Agents Chemother; 2024 May; 68(5):e0158323. PubMed ID: 38597667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predicting effects of antibiotic combinations using MICs determined at pharmacokinetically derived concentration ratios: in vitro model studies with linezolid- and rifampicin-exposed Staphylococcus aureus.
    Golikova MV; Strukova EN; Portnoy YA; Dovzhenko SA; Kobrin MB; Zinner SH; Firsov AA
    J Chemother; 2017 Oct; 29(5):267-273. PubMed ID: 28192070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics, toxicity and clinical efficacy of linezolid in Japanese pediatric patients.
    Ogami C; Tsuji Y; To H; Yamamoto Y
    J Infect Chemother; 2019 Dec; 25(12):979-986. PubMed ID: 31208925
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of pharmacokinetic interaction between linezolid and antacid in healthy volunteers.
    Grunder G; Zysset-Aschmann Y; Vollenweider F; Maier T; Krähenbühl S; Drewe J
    Antimicrob Agents Chemother; 2006 Jan; 50(1):68-72. PubMed ID: 16377669
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidemiology of clinically isolated methicillin-resistant Staphylococcus aureus (MRSA) and its susceptibility to linezolid and vancomycin in Egypt: a systematic review with meta-analysis.
    Azzam A; Khaled H; Mosa M; Refaey N; AlSaifi M; Elsisi S; Elagezy FK; Mohsen M
    BMC Infect Dis; 2023 Apr; 23(1):263. PubMed ID: 37101125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Linezolid Population Pharmacokinetics to Improve Dosing in Cardiosurgical Patients: Factoring a New Drug-Drug Interaction Pathway.
    Pai MP; Cojutti PG; Gerussi V; Della Siega P; Tascini C; Pea F
    Clin Infect Dis; 2023 Apr; 76(7):1173-1179. PubMed ID: 36424854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population Pharmacokinetics and Dosing Optimization of Linezolid in Pediatric Patients.
    Li SC; Ye Q; Xu H; Zhang L; Wang Y
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30642929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy, safety and pharmacokinetics of tedizolid versus linezolid in patients with skin and soft tissue infections in Japan - Results of a randomised, multicentre phase 3 study.
    Mikamo H; Takesue Y; Iwamoto Y; Tanigawa T; Kato M; Tanimura Y; Kohno S
    J Infect Chemother; 2018 Jun; 24(6):434-442. PubMed ID: 29530544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients.
    Matsumoto K; Shigemi A; Takeshita A; Watanabe E; Yokoyama Y; Ikawa K; Morikawa N; Takeda Y
    Int J Antimicrob Agents; 2014 Sep; 44(3):242-7. PubMed ID: 25108880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose Optimization of Combined Linezolid and Fosfomycin against
    Mao J; Li T; Zhang N; Wang S; Li Y; Peng Y; Liu H; Yang G; Yan Y; Jiang L; Liu Y; Li J; Huang X
    Microbiol Spectr; 2021 Dec; 9(3):e0087121. PubMed ID: 34851157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Linezolid: a review of its properties, function, and use in critical care.
    Hashemian SMR; Farhadi T; Ganjparvar M
    Drug Des Devel Ther; 2018; 12():1759-1767. PubMed ID: 29950810
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tedizolid: a new oxazolidinone antimicrobial.
    Kisgen JJ; Mansour H; Unger NR; Childs LM
    Am J Health Syst Pharm; 2014 Apr; 71(8):621-33. PubMed ID: 24688035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Systematic Review of Linezolid Pharmacokinetics/Pharmacodynamics in Patients Undergoing Continuous Renal Replacement Therapy: Does One Size Fit All?
    Liu Y; Ge XH; Guo HL; Chen F; Zhang Y; Xu J; Ji X; Miao HJ
    Curr Drug Metab; 2023; 24(1):70-77. PubMed ID: 36579392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Linezolid for the treatment of resistant gram-positive cocci.
    Bain KT; Wittbrodt ET
    Ann Pharmacother; 2001 May; 35(5):566-75. PubMed ID: 11346064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decreased serum linezolid concentrations in two patients receiving linezolid and rifampicin due to bone infections.
    Hoyo I; Martínez-Pastor J; Garcia-Ramiro S; Climent C; Brunet M; Cuesta M; Mensa J; Soriano A
    Scand J Infect Dis; 2012 Jul; 44(7):548-50. PubMed ID: 22385321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.